Maravai LifeSciences' (MRVI) Market Perform Rating Reaffirmed at William Blair

William Blair restated their market perform rating on shares of Maravai LifeSciences (NASDAQ:MRVI - Free Report) in a research note published on Friday morning, Marketbeat Ratings reports.

A number of other analysts have also commented on the company. The Goldman Sachs Group lowered their price objective on Maravai LifeSciences from $8.00 to $7.00 and set a "neutral" rating for the company in a research report on Tuesday, October 8th. Wells Fargo & Company initiated coverage on shares of Maravai LifeSciences in a report on Tuesday, August 27th. They set an "overweight" rating and a $10.00 target price for the company. UBS Group upped their price objective on Maravai LifeSciences from $8.50 to $11.00 and gave the company a "neutral" rating in a report on Thursday, August 8th. Royal Bank of Canada reissued an "outperform" rating and issued a $15.00 target price on shares of Maravai LifeSciences in a research note on Friday, August 16th. Finally, Morgan Stanley cut Maravai LifeSciences from an "overweight" rating to an "equal weight" rating and lowered their price target for the company from $11.00 to $10.00 in a research note on Tuesday, August 13th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Maravai LifeSciences presently has a consensus rating of "Moderate Buy" and an average target price of $10.33.

Maravai LifeSciences Stock Down 36.4 %

Maravai LifeSciences stock traded down $2.85 during mid-day trading on Friday, hitting $4.99. The company's stock had a trading volume of 10,253,280 shares, compared to its average volume of 2,241,763. The firm's 50 day moving average is $8.18 and its 200 day moving average is $8.51. The company has a debt-to-equity ratio of 0.71, a current ratio of 10.00 and a quick ratio of 9.28. The company has a market cap of $1.26 billion, a PE ratio of -4.83 and a beta of 0.02. Maravai LifeSciences has a 52-week low of $4.52 and a 52-week high of $11.56.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.08) earnings per share (EPS) for the quarter. The company had revenue of $73.40 million for the quarter, compared to the consensus estimate of $71.64 million. Maravai LifeSciences had a negative return on equity of 4.78% and a negative net margin of 47.41%. The company's revenue was up 6.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.06) EPS. On average, analysts anticipate that Maravai LifeSciences will post -0.17 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its position in Maravai LifeSciences by 310.2% in the 2nd quarter. GAMMA Investing LLC now owns 3,585 shares of the company's stock valued at $26,000 after acquiring an additional 2,711 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Maravai LifeSciences in the second quarter valued at about $32,000. Headlands Technologies LLC acquired a new position in shares of Maravai LifeSciences during the first quarter worth about $42,000. Venturi Wealth Management LLC bought a new position in shares of Maravai LifeSciences during the third quarter worth about $47,000. Finally, Blue Trust Inc. acquired a new stake in Maravai LifeSciences in the 2nd quarter valued at approximately $44,000. Institutional investors and hedge funds own 50.25% of the company's stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.